In addition to its core operations, the company actively deploys surplus capital into strategic investments, including equities (both listed and unlisted) and mutual funds. Its manufacturing facilities are located in Roorkee and Una, and are regularly upgraded to align with international quality standards.

The company has received notable industry recognitions, such as:

“Best Innovation in Process & Formulation Development” from the Ministry of Health & Family Welfare
“Pharma Excellence Award 2018” by ASSOCHAM
Business Segments

Martin & Harris Laboratories operates through two key segments:

1. Pharmaceutical Manufacturing
This is the company’s primary business, contributing approximately 52% of total revenue, focused on the production of pharmaceutical and chemical products.

2. Derivative & Investment Segment
Accounting for around 48% of revenue, this division generates income through investments in mutual funds, and both listed and unlisted equities, along with other financial instruments.

Financial Highlights (FY21–FY24)
Revenue reached its peak at ₹205 crore in FY23 before declining to ₹146 crore in FY24.
Gross margins remained robust, fluctuating between 61.9% and 77.07% over the four-year period.
EBITDA dropped significantly to ₹26 crore in FY24 from ₹72 crore in FY23, indicating reduced operational efficiency.
Operating Profit Margin (OPM) declined to 17.81% in FY24 after maintaining levels above 35% in previous years.
Profit After Tax (PAT) stood at ₹40 crore in FY24, still positive but lower than prior years, with Net Profit Margin (NPM) falling to 27.4%.
Earnings Per Share (EPS) showed a declining trend, decreasing from ₹170.43 in FY23 to ₹100.25 in FY24.
The balance sheet remains strong, with total assets rising to ₹662 crore and reserves reaching ₹628 crore in FY24.

Pros
Diversified Revenue Streams: Balanced contribution from pharmaceutical operations and investment income enhances financial stability.
Low Debt Levels: Minimal borrowing results in low finance costs and a healthy capital structure.
Strong Financial Base: High reserves and asset base reflect solid long-term strength.

Cons
Decline in Revenue (FY24): A noticeable drop in topline may indicate operational or market-related challenges.
Pressure on Margins: Significant decline in EBITDA and operating margins in the latest fiscal year.
Reliance on Investment Income: A substantial portion of revenue comes from non-core activities, increasing dependency on market performance.